Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment,Different amyloid β42 preparations induce different cell death pathways in the model of SH-SY5Y neuroblastoma cells | Cellular & Molecular Biology Letters | Full Text,Frontiers | Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer,479KB,Frontiers | Targeting amino acid-metabolizing enzymes for cancer immunotherapy